Score Overview
Explore the 2021 public Archive ranking →
Where United Therapeutics Corporation has ranked, year by year
Showing 10 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- UTHR
2010: 36.5% · 2021: 22.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 481.47 | — |
1 Year2025-09-29 | $ 424.31 | 13.47% |
5 Years2021-09-29 | $ 185.50 | 159.55% |
10 Years2016-09-29 | $ 115.02 | 318.60% |
20 Years2006-09-29 | $ 26.31 | 18x |
All Time1999-06-17 | $ 6.09 | 79x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time1999-06-17 |
|---|---|---|---|---|---|---|
| Price | $ 481.47 | $ 424.31 | $ 185.50 | $ 115.02 | $ 26.31 | $ 6.09 |
| Return | — | 13.47% | 159.55% | 318.60% | 18x | 79x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3.15B | $ 1.31B | $ 2.66B |
| 2025 | $ 3.18B | $ 1.33B | $ 1.55B |
| 2024 | $ 2.87B | $ 1.19B | $ 3.26B |
| 2023 | $ 2.32B | $ 984M | $ 2.99B |
| 2022 | $ 1.93B | $ 727M | $ 2.83B |
| 2021 | $ 1.68B | $ 475M | $ 1.93B |
| 2020 | $ 1.48B | $ 514M | $ 1.83B |
| 2019 | $ 1.44B | -$ 104M | $ 1.48B |
| 2018 | $ 1.62B | $ 589M | $ 1.41B |
| 2017 | $ 1.72B | $ 417M | $ 1.43B |
| 2016 | $ 1.59B | $ 713M | $ 1.05B |
| 2015 | $ 1.46B | $ 651M | $ 953M |
| 2014 | $ 1.28B | $ 340M | $ 695M |
| 2013 | $ 1.11B | $ 174M | $ 693M |
| 2012 | $ 916M | $ 304M | $ 479M |
| 2011 | $ 743M | $ 217M | $ 403M |
| 2010 | $ 603M | $ 105M | $ 627M |
| 2009 | $ 369M | $ 19M | $ 229M |
| 2008 | $ 281M | -$ 42M | $ 236M |
| 2007 | $ 210M | $ 19M | $ 290M |
| 2006 | $ 159M | $ 73M | $ 227M |
| 2005 | $ 115M | $ 65M | $ 125M |
| 2004 | $ 73M | $ 15M | $ 82M |
| 2003 | $ 53M | -$ 9M | $ 68M |
| 2002 | $ 30M | -$ 23M | $ 122M |
| 2001 | $ 5M | -$ 37M | $ 56M |
| 2000 | $ 2M | -$ 75M | $ 215M |
| IPO1999 | $ 400K | -$ 33M | $ 51M |
United Therapeutics Corporation fundamental performance
Between 2020 and 2025, revenue grew from $ 1.48B to $ 3.18B and net income grew from $ 514M to $ 1.33B. Revenue increased in 4 of those 5 years; net income in 4.
Across United Therapeutics Corporation's full reported history, from 1999 to 2025, revenue grew from $ 400K to $ 3.18B and net income went from -$ 33M to $ 1.33B. Revenue increased in 89% of the years measured; net income in 70%.
United Therapeutics Corporation currently holds a 20-year HDB Score of 7.6 out of 10. How the HDB Score is calculated.
Membership
Continue UTHR’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
